Compare SMX & DARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SMX | DARE |
|---|---|---|
| Founded | N/A | 2015 |
| Country | Ireland | United States |
| Employees | 19 | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.7M | 21.6M |
| IPO Year | N/A | 2014 |
| Metric | SMX | DARE |
|---|---|---|
| Price | $14.20 | $2.50 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | ★ 4.2M | 1.1M |
| Earning Date | 04-23-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,807,885.00 |
| Revenue This Year | N/A | $2,115.12 |
| Revenue Next Year | N/A | $122.62 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.75 | $1.27 |
| 52 Week High | $490.00 | $9.19 |
| Indicator | SMX | DARE |
|---|---|---|
| Relative Strength Index (RSI) | 71.17 | 52.68 |
| Support Level | $1.10 | $1.79 |
| Resistance Level | $20.09 | $2.54 |
| Average True Range (ATR) | 1.15 | 0.34 |
| MACD | 1.24 | 0.01 |
| Stochastic Oscillator | 59.96 | 28.09 |
SMX (Security Matters) PLC provides one solution to solve both authentication and track and trace challenges in order to uphold supply chain integrity and provide quality assurance and brand accountability to producers of goods. Its technology works as a track and trace system using a marker, a reader, and an algorithm to identify embedded sub-molecular particles in order to track and trace different components along a production process (or any other marked good along a supply chain) to the end producer.
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.